Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar KirkDCJ (< 20) Submitted: 7/14/2011 3:15:07 PM : Outperform Start Price: $19.95 SGEN Score: +2.96

Cleared major hurdle with panel today. Possible first successful mover in "toxic payload" antibody for cancers. Needs to move on to more common cancers (like IMGN's HER2+ breast cancer possibility) for major financial success...but great first step with Hodgkin's and maybe large cell lymphoma.

Report this Post Reply

Featured Broker Partners


Advertisement